Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.

abstract：:Developed by Bayer in Germany, nifedipine was shown to be effective in the treatment of patients with angina pectoris by Japanese investigators. Professor Kimura first reported the efficacy of nifedipine in patients with angina pectoris and those findings have been replicated in numerous trials conducted since then. C...

journal_title：Drugs

authors： Hosoda S

更新日期：2006-01-01 00:00:00

abstract：:Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extrac...

journal_title：Drugs

authors： Kumana CR,Yuen KY

更新日期：1994-06-01 00:00:00

abstract：:A once-daily preservative-free fixed combination ophthalmic solution containing tafluprost 0.0015 % and timolol 0.5 % (hereafter referred to as tafluprost/timolol) [Taptiqom(®)] has been developed to lower intraocular pressure (IOP) whilst avoiding damage to the ocular surface associated with preservatives such as ben...

journal_title：Drugs

authors： Hoy SM

更新日期：2015-10-01 00:00:00

abstract：:The simplest response to the question, what is the prevalence of hypertension in the United States today?, is given by a currently popular slogan: 23,000,000 Americans have hypertension. It is clear that the problem is large in scale, but this figure alone is an insufficient guide to many practical issues. The prevale...

journal_title：Drugs

authors： Labarthe DR

更新日期：1976-01-01 00:00:00

abstract：:The hyperkinetic syndrome is a symptom complex of hyperactivity, short attention span, distractibility, impulsivity, learning difficulties, other behaviour problems and 'equivocal' neurological signs. However, none of these terms has ever been objectively defined and at present diagnosis is largely a matter of clinica...

journal_title：Drugs

authors： Werry JS

更新日期：1976-01-01 00:00:00

abstract：:Second-generation histamine H1 receptor antagonists (antihistamines) have been developed to reduce or eliminate the sedation and anticholinergic adverse effects that occur with older H1 receptor antagonists. This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetiriz...

journal_title：Drugs

authors： Slater JW,Zechnich AD,Haxby DG

更新日期：1999-01-01 00:00:00

abstract：:Sulbactam 1g and ampicillin 2g were administered intravenously to 12 patients, and concentrations of the drugs were determined in the serum and myometrium for up to 120 minutes after infusion. The ratio of sulbactam to ampicillin was about 1:2 in the serum and myometrium. Both drugs penetrated well into the myometrium...

journal_title：Drugs

authors： Schwiersch U,Lang N,Wildfeuer DA

更新日期：1986-01-01 00:00:00

abstract：:Insulin glulisine (Apidra) is a human insulin analogue approved for the improvement of glycaemic control in adults, adolescents and children with diabetes mellitus. It has similar binding properties, and is associated with a faster onset but similar level of glucose disposal, to regular human insulin (RHI). Insulin gl...

journal_title：Drugs

authors： Garnock-Jones KP,Plosker GL

更新日期：2009-05-29 00:00:00

abstract：:The original article has been corrected. ...

journal_title：Drugs

authors： Lamb YN

更新日期：2020-03-01 00:00:00

abstract：:Arachidonic acid is normally stored in membrane-bound phospholipids and released by the action of phospholipases. Enzymatic conversion of released arachidonic acid into biologically active derivatives proceeds through one of several routes. Cyclo-oxygenase converts arachidonic acid to unstable cyclic endoperoxides fro...

journal_title：Drugs

authors： Samuelsson B

更新日期：1987-01-01 00:00:00

abstract：:Certolizumab pegol (Cimzia(®)) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor (TNF)-α. The drug is indicated for subcutaneous use every 2 or 4 weeks (q2w or q4w) for the treatment of adults with mo...

journal_title：Drugs

authors： Deeks ED

更新日期：2013-01-01 00:00:00

abstract：:Multiple drugs are now available for the treatment of overactive bladder. Currently, the pharmacological approach is to deal with the problem at the neuromuscular junction by attempting to stop the activity of the neurotransmitter with antimuscarinic medications. This article reviews the positive and negative aspects ...

journal_title：Drugs

authors： Appell RA

更新日期：2006-01-01 00:00:00

abstract：:Opioid dependence, manifesting as addiction to heroin and pharmaceutical opioids is increasing. Internationally, there are an estimated 15.6 million illicit opioid users. The global economic burden of opioid dependence is profound both in terms of HIV and hepatitis C virus transmission, direct healthcare costs, and in...

journal_title：Drugs

authors： Tetrault JM,Fiellin DA

更新日期：2012-01-22 00:00:00

abstract：UNLABELLED:Almotriptan is a selective serotonin 5-HT(1B/1D) receptor agonist ('triptan'). Its efficacy and tolerability have been assessed in a number of randomised, controlled trials in over 4800 adults with moderate or severe attacks of migraine. Oral almotriptan has a rapid onset of action (significant headache reli...

journal_title：Drugs

authors： Keam SJ,Goa KL,Figgitt DP

更新日期：2002-01-01 00:00:00

abstract：:Pomalidomide (Imnovid®; Pomalyst®), an analogue of thalidomide, is an immunomodulatory agent, with several mechanisms of action (both direct and indirect) thought to be involved in its anti-myeloma activity. Oral pomalidomide is available in several countries for use in combination with low-dose dexamethasone in adult...

journal_title：Drugs

authors： Hoy SM

更新日期：2017-11-01 00:00:00

abstract：:Migalastat (Galafold™)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations. Fabry disease is a rare disorder that results in a deficiency or absen...

journal_title：Drugs

authors： Markham A

更新日期：2016-07-01 00:00:00

abstract：:Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in...

journal_title：Drugs

authors： Markham A,Keam SJ

更新日期：2019-06-01 00:00:00

abstract：:The efficacy and tolerability of nimesulide were compared with those of paracetamol in a nonblind randomised study that recruited 110 children (64 males, 46 females; aged 3 to 6 years) with inflammation of the upper respiratory tract and fever. Nimesulide suspension (1.5 mg/kg 3 times daily) or paracetamol syrup (10 m...

journal_title：Drugs

authors： Polidori G,Titti G,Pieragostini P,Comito A,Scaricabarozzi I

更新日期：1993-01-01 00:00:00

abstract：:Scleroderma or systemic sclerosis is a rare condition with many clinical manifestations including Raynaud's phenomenon. As with many other rarely encountered diseases, drug therapy for scleroderma is often empirical with little evidence in the form of randomised controlled trials to aid drug choice. Raynaud's phenomen...

journal_title：Drugs

authors： Leighton C

更新日期：2001-01-01 00:00:00

abstract：:The common clinical problem of recurrent symptomatic urinary tract infections (UTI) in young women may be inconvenient and distressing to both the patient and her family, particularly if the infections are not managed in a rational manner. A suggested approach is included in table 1. ...

journal_title：Drugs

authors： Bailey RR

更新日期：1977-02-01 00:00:00

abstract：:We have analysed the published literature on eptacog alfa (recombinant factor VIIa; rFVIIa) for nonhaemophiliac conditions with the aim of determining its current place in therapy. Initial surgical and/or medical management is required for any patient with life-threatening bleeding. In those with continued life-threat...

journal_title：Drugs

authors： Mallarkey G,Brighton T,Thomson A,Kaye K,Seale P,Gazarian M

更新日期：2008-01-01 00:00:00

abstract：:Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methyl-hexanoic acid, has a similar pharmacological profile to that of its developmental predecessor gabapentin, but showed greater analgesic activity in rodent models of neuropathic pain. The exact mechanism of action of pregabalin is unclear, a...

journal_title：Drugs

authors： Frampton JE,Scott LJ

更新日期：2004-01-01 00:00:00

abstract：:Along with nausea and vomiting, postanaesthetic shivering is one of the leading causes of discomfort for patients recovering from general anaesthesia. The distinguishing factor during electromyogram recordings between patients with postanaesthetic shivering and shivering in fully awake patients is the existence of clo...

journal_title：Drugs

authors： Alfonsi P

更新日期：2001-01-01 00:00:00

abstract：:Intravenous inotuzumab ozogamicin (Besponsa®; Pfizer) is an anti-CD22 monoclonal antibody-calicheamicin conjugate that binds to CD22-expressing tumour cells. Upon binding, the complex is internalised and the cytotoxic calicheamicin derivative is released inside the cell, inducing double-strand DNA breakage and subsequ...

journal_title：Drugs

authors： Lamb YN

更新日期：2017-09-01 00:00:00

abstract：:Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductio...

journal_title：Drugs

authors： Pereira MJ,Eriksson JW

更新日期：2019-02-01 00:00:00

abstract：:During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...

journal_title：Drugs

authors： Krivitzky A,Nguyen G,Gaudouen Y,Legrand M,Cohen R

更新日期：1998-01-01 00:00:00

abstract：:The objective of surgical prophylaxis is to prevent wound infections associated with surgery. The rates of wound infections vary according to the procedure: less than 3 infections per 100 for clean procedures; up to 4 per 100 for clean-contaminated procedures; and up to 9 per 100 for contaminated procedures. Surgical ...

journal_title：Drugs

authors： Dellamonica P,Bernard E

更新日期：1993-01-01 00:00:00

abstract：:The binding of drugs to proteins is an important pharmacokinetic parameter. Many methods are available for the study of drug protein binding phenomena and there are also many ways to interpret the binding data. Although much emphasis has been placed on the binding of drugs in the plasma, binding also takes place in th...

journal_title：Drugs

authors： McElnay JC,D'Arcy PF

更新日期：1983-05-01 00:00:00

abstract：:The chronic fatigue syndrome (CFS) was formally defined in 1988 to describe a syndrome of severe and disabling fatigue of uncertain aetiology associated with a variable number of somatic and/or psychological symptoms. CFS has been reported in most industrialised countries and is most prevalent in women aged between 20...

journal_title：Drugs

authors： Blondel-Hill E,Shafran SD

更新日期：1993-10-01 00:00:00

abstract：:Macitentan (Opsumit(®)) is an orally active, dual endothelin receptor antagonist (ERA) with tissue targeting properties. Macitentan was approved recently in the EU (as monotherapy or combination therapy) for the long-term treatment of pulmonary arterial hypertension (PAH) in adults of WHO functional class II or III, a...

journal_title：Drugs

authors： Dhillon S

更新日期：2014-09-01 00:00:00